Nkarta said it expects initial data from a clinical trial testing its cell therapy candidate NKX019 in adults with ANCA-associated vasculitis (AAV) and other autoimmune diseases to be presented later this year. The Phase 1/2 Ntrust-2 trial (NCT06733935) is testing several doses of NKX019 in up to…
News
People with ANCA-associated vasculitis (AAV) are more likely to have worse kidney function and related outcomes if their self-targeting antibodies, called ANCAs, activate immune cells via the Fc gamma receptor protein, a study suggested. “[Fc gamma-driven] ANCA can be a biomarker for poor kidney prognosis in ANCA-associated vasculitis,” the…
Adding plasma exchange, a blood-cleaning procedure, to standard therapy to induce disease remission may help reduce short-term mortality in people with ANCA-associated vasculitis (AAV) with poor kidney function, a study in China shows. Still, mortality rates at one year were comparable between patients who received plasma exchange and those…
In most people with kidney damage due to ANCA-associated vasculitis (AAV), outcomes from initial treatment to bring the disease under control are similar across commonly used immunosuppressive therapies, including cyclophosphamide and rituximab. That’s according to a study analyzing data from hundreds of patients at several European centers.
People with ANCA-associated vasculitis (AAV) who develop bronchiectasis — a chronic lung condition marked by permanent widening of certain parts of the airways — may face a higher risk of serious infections and death, according to a new study. The researchers found that bronchiectasis in individuals with granulomatosis with polyangiitis…
A risk score that combines blood tests and kidney biopsy findings performed among the strongest tools for predicting kidney failure in people with ANCA-associated vasculitis (AAV), a small study suggests. The analysis also showed that all three risk scoring systems evaluated remained linked to the risk of kidney failure…
At diagnosis, half of adults with ANCA-associated vasculitis (AAV) already have signs of interstitial lung disease (ILD), a condition marked by inflammation and progressive scarring of lung tissue, according to a new single-center study in Italy. Evidence of lung disease was particularly prevalent among those with microscopic polyangiitis (MPA),…
ANCA-associated vasculitis (AAV) patients with antibodies targeting the myeloperoxidase (MPO) protein have higher levels of immune-activating pieces of the C3 protein in their urine, and these are closely associated with measures of disease severity, a small study showed. “These fragments may serve as sensitive, [noninvasive] biomarkers for [kidney] immune…
Lung complications are common among adults with ANCA-associated vasculitis (AAV), affecting four in five individuals throughout their disease course, with some developing lasting damage, a study found. According to the new analysis of more than 1,000 patients in the U.S. and Canada, patterns of lung involvement differed between those…
Adults with ANCA-associated vasculitis (AAV) who test positive for antibodies against the myeloperoxidase (MPO) protein may face cardiovascular events sooner than those with antibodies against the proteinase-3 (PR3) protein, according to a new study. The French study analyzed data from 402 adults with AAV. While the overall proportion of…
Recent Posts
- Initial data from trial of AAV therapy NKX019 expected this year
- Understanding the different types of fatigue that come with vasculitis
- Study ties specific immune pathway to kidney damage in AAV
- Plasma exchange therapy may boost short-term survival in AAV
- When talking with patients, we should use language that creates connection